加速药物研发合作组织：狼疮肾炎 1 期研究的组织结构和初步数据。
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
机构信息
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
出版信息
Arthritis Care Res (Hoboken). 2020 Feb;72(2):233-242. doi: 10.1002/acr.24066. Epub 2020 Jan 13.
Abstract
The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers to apply high-throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for analysis of a large cohort of LN samples in phase 2 and provides a model for establishing similar discovery cohorts.
摘要
加速药物研发合作组织（AMP）狼疮网络是由美国国立卫生研究院、制药公司、非营利性利益相关者和多个学术中心的狼疮研究人员组成的合作伙伴关系，旨在将高通量技术应用于狼疮肾炎（LN）患者的肾组织、尿液和血液分析。AMP 网络向社区提供公开数据，旨在产生新的科学假设，改进诊断和治疗工具，从而改善疾病结果。我们在这里介绍 AMP 狼疮网络的结构，并总结了 1 期研究的初步结果。1 期研究的成功完成为 2 期对大量 LN 样本的分析奠定了基础，并为建立类似的发现队列提供了模式。
相似文献
1
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
Arthritis Care Res (Hoboken). 2020 Feb;72(2):233-242. doi: 10.1002/acr.24066. Epub 2020 Jan 13.
2
The Power of Systems Biology: Insights on Lupus Nephritis from the Accelerating Medicines Partnership.
Rheum Dis Clin North Am. 2021 Aug;47(3):335-350. doi: 10.1016/j.rdc.2021.04.003. Epub 2021 Jun 16.
3
Leveraging public private partnerships to innovate under challenging budget times.
Curr Top Med Chem. 2014;14(3):326-9. doi: 10.2174/1568026613666131127155703.
4
Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):545-8. doi: 10.1586/erp.12.59. Epub 2012 Nov 8.
5
An audience with...Francis Collins. Interviewed by Asher Mullard.
Nat Rev Drug Discov. 2011 Jan;10(1):14. doi: 10.1038/nrd3357. Epub 2010 Dec 10.
6
A principled partnership between academic medicine and industry.
Medscape J Med. 2008;10(8):198. Epub 2008 Aug 22.
7
The innovative medicines initiative: a European response to the innovation challenge.
Clin Pharmacol Ther. 2012 Mar;91(3):418-25. doi: 10.1038/clpt.2011.321. Epub 2012 Feb 8.
8
Achieving a transparent, actionable framework for public-private partnerships for food and nutrition research.
Am J Clin Nutr. 2015 Jun;101(6):1359-63. doi: 10.3945/ajcn.115.112805.
9
How academic labs can approach the drug discovery process as a way to synergize with big pharma.
Trends Microbiol. 2013 Jun;21(6):261-4. doi: 10.1016/j.tim.2013.03.006.
10
Protecting NIH's Integrity and Trustworthiness in Public-Private Partnerships.
JAMA. 2018 Aug 7;320(5):439-440. doi: 10.1001/jama.2018.7625.
引用本文的文献
1
Pseudo-spectral angle mapping for pixel and cell classification in highly multiplexed immunofluorescence images.
J Med Imaging (Bellingham). 2024 Nov;11(6):067502. doi: 10.1117/1.JMI.11.6.067502. Epub 2024 Dec 10.
2
Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells.
Sci Transl Med. 2024 Nov 27;16(775):eadl1666. doi: 10.1126/scitranslmed.adl1666.
3
Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.
Rheumatology (Oxford). 2025 May 1;64(5):2676-2687. doi: 10.1093/rheumatology/keae559.
4
Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response.
Arthritis Rheumatol. 2024 Nov;76(11):1611-1622. doi: 10.1002/art.42941. Epub 2024 Aug 9.
5
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.
Arthritis Res Ther. 2024 Feb 20;26(1):54. doi: 10.1186/s13075-024-03275-z.
6
Urinary biomarkers associated with podocyte injury in lupus nephritis.
Front Pharmacol. 2024 Jan 19;15:1324540. doi: 10.3389/fphar.2024.1324540. eCollection 2024.
7
Pseudo-spectral angle mapping for automated pixel-level analysis of highly multiplexed tissue image data.
bioRxiv. 2024 Jan 11:2024.01.09.574920. doi: 10.1101/2024.01.09.574920.
8
Kidney and urine cell transcriptomics in IgA nephropathy and lupus nephritis: a narrative review.
Clin Kidney J. 2023 Nov 9;17(1):sfad121. doi: 10.1093/ckj/sfad121. eCollection 2024 Jan.
9
Single cell spatial transcriptomic profiling of childhood-onset lupus nephritis reveals complex interactions between kidney stroma and infiltrating immune cells.
bioRxiv. 2023 Nov 13:2023.11.09.566503. doi: 10.1101/2023.11.09.566503.
10
Precision Medicine in Nephrology: An Integrative Framework of Multidimensional Data in the Kidney Precision Medicine Project.
Am J Kidney Dis. 2024 Mar;83(3):402-410. doi: 10.1053/j.ajkd.2023.08.015. Epub 2023 Oct 13.
本文引用的文献
1
Fast, sensitive and accurate integration of single-cell data with Harmony.
Nat Methods. 2019 Dec;16(12):1289-1296. doi: 10.1038/s41592-019-0619-0. Epub 2019 Nov 18.
2
The immune cell landscape in kidneys of patients with lupus nephritis.
Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17.
3
Comprehensive Integration of Single-Cell Data.
Cell. 2019 Jun 13;177(7):1888-1902.e21. doi: 10.1016/j.cell.2019.05.031. Epub 2019 Jun 6.
4
Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.
Nat Immunol. 2019 Jul;20(7):915-927. doi: 10.1038/s41590-019-0386-1. Epub 2019 May 20.
5
Integrative single-cell analysis.
Nat Rev Genet. 2019 May;20(5):257-272. doi: 10.1038/s41576-019-0093-7.
6
All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014.
Arthritis Rheumatol. 2019 Mar;71(3):403-410. doi: 10.1002/art.40729. Epub 2019 Jan 9.
7
Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus.
Pediatr Nephrol. 2019 Jan;34(1):117-128. doi: 10.1007/s00467-018-4049-5. Epub 2018 Aug 29.
8
Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target.
Am J Ophthalmol. 2018 Feb;186:152-163. doi: 10.1016/j.ajo.2017.11.025. Epub 2017 Dec 13.
9
The Reactome Pathway Knowledgebase.
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655. doi: 10.1093/nar/gkx1132.
10
Reversed graph embedding resolves complex single-cell trajectories.
Nat Methods. 2017 Oct;14(10):979-982. doi: 10.1038/nmeth.4402. Epub 2017 Aug 21.
Zotero 插件